無料プレビュー

Latigo Biotherapeutics Inc. (LTGO) · NASDAQ

プロフィール

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

主要指標

株価: $14.79 (-4.70%)
時価総額: 9億ドル
PER（今期予想）: —
PBR: —
配当利回り: —
52週レンジ: $14.60 – $25.93
業種: Healthcare / Medical - Pharmaceuticals
上場: NASDAQ
構成銘柄: —

比較会社: RPRX Royalty Pharma plc、CORT Corcept Therapeutics Incorporated、WBA Walgreens Boots Alliance, Inc.、KNSA Kiniksa Pharmaceuticals International, plc、LQDA Liquidia Corporation、PBH Prestige Consumer Healthcare Inc.、PCRX Pacira BioSciences, Inc.、COLL Collegium Pharmaceutical, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

更新: 2026-10-09